Armed with deals, dollars and the promise of upcoming data, Zymeworks files $75M IPO
A little more than a year ago, as Zymeworks CEO Ali Tehrani was reeling in a $61.5 million crossover round, the biotech CEO told me that he had a two-year runway and a shot at being opportunistic in filing for an IPO. This morning, Tehrani concluded that the time was right—or at least necessary.
Zymeworks $ZYME has been blitzing its way through a series of partnerships and expansion projects focused on its bispecific antibodies and armed ADCs, two platforms Zymeworks will now depend on to raise at least $75 million in an IPO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.